



Effects of heart failure on cerebral blood flow in COPD: Rest and exercise



Mayron F. Oliveira^a, Maria Clara Alencar^a, Flavio Arbex^a, Aline Souza^a, Priscila Sperandio^a, Luiz Medina^a, Wladimir M. Medeiros^a, Daniel M. Hirai^{a,b}, Denis E. O'Donnell^b, J. Alberto Neder^{a,b,*}

^a Pulmonary Function and Clinical Exercise Physiology Unit (SEFICE), Division of Respiratory, Federal University of Sao Paulo, Sao Paulo, Brazil

^b Respiratory Investigation Unit & Laboratory of Clinical Exercise Physiology, Queen's University & Kingston General Hospital, Kingston, ON, Canada

ARTICLE INFO

Article history:

Received 5 August 2015

Received in revised form 7 October 2015

Accepted 10 October 2015

Available online 31 October 2015

Keywords:

Cerebral oxygenation

Chronic obstructive pulmonary disease

Comorbidity

Near-infrared spectroscopy

ABSTRACT

Cerebral blood flow (CBF) and oxygenation (COx) are generally well-preserved in COPD. It is unknown whether prevalent cardiovascular co-morbidities, such as heart failure, may impair CBF and COx responses to exertion. Eighteen males with moderate-to-severe COPD (8 with and 10 without overlapping heart failure) underwent a progressive exercise test with pre-frontal CBF and COx measurements (indocyanine green and near-infrared spectroscopy). Mean arterial pressure and cardiac output were lower from rest to exercise in overlap. Only COPD patients demonstrated an increase in arterialized PCO₂ towards the end of progressive exercise. CBF index was consistently higher and increased further by ~40% during exercise in COPD whereas a ~10% reduction was observed in overlap. COx was lower in overlap despite preserved arterial oxygenation. In conclusion, heart failure introduces pronounced negative effects on CBF and COx in COPD which may be associated with clinically relevant outcomes, including dyspnea, exercise intolerance, cerebrovascular disease and cognitive impairment.

© 2015 Elsevier B.V. All rights reserved.

1. Introduction

Cerebral blood flow (CBF) is regulated via the integration of multiple physiological adjustments, including those in blood pressure, cardiac output, neurovascular coupling, arterial blood gas tensions and autonomic nervous system activation (Ogoh and Ainslie, 2009; Willie et al., 2014; Brassard et al., 2014). Physical exercise influences all of these processes making CBF regulation a formidable challenge for patients with cardiopulmonary and metabolic diseases (Kim et al., 2012, 2015).

In this context, it is rather surprising that patients with stable chronic obstructive pulmonary disease (COPD) usually present with preserved (or increased) CBF at rest (Yildiz et al., 2012; Cornwell and Levine, 2015; Alosco and Hayes, 2015) and during exercise (Oliveira et al., 2012; Vogiatzis et al., 2013; Hartmann et al., 2014). This finding might be explained by their tendency to upregulate PaCO₂, a potent cerebral vasodilator (Ogoh and Ainslie, 2009). This might become more evident during exercise as patients are frequently unable to increase ventilation to properly wash-out

CO₂ released from lactate buffering or, in more severe COPD, CO₂ derived from cellular metabolism (O'Donnell et al., 2014). At least in those who are not overtly hypoxemic at rest, effective cerebral vasodilation may offset mild-to-moderate decrements in PaO₂ thereby preserving cerebral oxygenation (COx) (Jensen et al., 2002; Van de Ven et al., 2001). In fact, we (Oliveira et al., 2012) and others (Higashimoto et al., 2011) have found similar increases in COx (measured by near-infrared spectroscopy) during exercise in non-to mildly-hypoxemic COPD patients and healthy controls.

A different scenario, however, may emerge in the presence of a common and disabling co-morbidity of COPD: heart failure (Rutten et al., 2006; Güder and Rutten, 2014). In fact, impaired resting CBF, (Choi et al., 2006; Kim et al., 2012) which is further worsened under the stress of exercise, (Koike et al., 2004, 2006; Fu et al., 2011) has been reported in heart failure with reduced left ventricular ejection fraction. These abnormalities have been ascribed to the combined effects of impaired cerebral auto-regulation, decreased mean arterial pressure and cardiac output, alveolar hyperventilation (i.e., low PaCO₂) and sympathetic over-excitation. (Alosco and Hayes, 2015) Of note, patients with coexistent COPD-heart failure (“overlap”) have higher prevalence of cerebrovascular disease (Rutten et al., 2006; Güder and Rutten, 2014) and cognition disorders (Alosco et al., 2014) than COPD patients without heart failure. Interestingly, we found previously lower COx during rapidly-incremental

* Corresponding author at: 102 Stuart Street, Kingston, Ontario, K7L 2V6, Canada. Fax: +1 613 549 1459.

E-mail address: alberto.neder@queensu.ca (J.A. Neder).




Fig. 1. Cerebral blood flow index (BFI) calculation based on indocyanine green kinetics measured by near-infrared spectroscopy in representative COPD and overlap patients.

exercise in overlap compared to COPD (Oliveira et al., 2013). Collectively, these findings prompted the hypothesis that the reported “protective” effects of COPD on exercise CBF could be overridden by the ominous pathophysiological consequences of heart failure on cerebral hemodynamics (Koike et al., 2004; Choi et al., 2006; Koike et al., 2006; Fu et al., 2011; Kim et al., 2012).

The aim of this study was thus to investigate the influence of heart failure on CBF and CO_x in COPD patients from rest to exercise. We specifically postulated that, compared with age- and gender-matched COPD, overlap patients would present with reduced CBF thereby leading to lower CO_x.

2. Methods

2.1. Subjects

Eighteen sedentary males with well-established moderate-to-severe COPD (Global Initiative for Obstructive Lung Disease stages 2 and 3) (Vestbo et al., 2013) comprised the study group. Eight patients had echocardiographic evidences of heart failure with reduced left ventricular ejection fraction (<50%). Patients were seen prospectively by the same respirologists and cardiologists. Disease treatment for both diseases was decided by consensus and optimized carefully before study entry. Main exclusion criteria included: long-term O₂ therapy, recent (within a year) rehabilitation, previous stroke or transitory ischemic attack, osteomuscular limitation to cycling, type I or non-controlled type II diabetes mellitus and clinical history of peripheral (including carotid) arterial disease. All subjects gave written informed consent and the study was approved by the Medical Ethics committee of the Sao Paulo Hospital, Sao Paulo, Brazil.

2.2. Measurements

2.2.1. Lung function

Spirometry, lung diffusing capacity, and static lung volumes were evaluated (1085 ELITE DTM, Medical Graphics). Resting blood gases were obtained from samples from the radial artery.

2.2.2. Cardiopulmonary exercise testing

Patients performed a four-stage (4 min each with 4 min rest in-between) cycle ergometer test at 20%, 40%, 60% and 80% of the peak workload (WR_{peak}) achieved on a previous incremental test. Oxygen uptake ($\dot{V}O_2$, mL/min), carbon dioxide output ($\dot{V}CO_2$, mL/min), respiratory exchange ratio (R), minute ventilation (VE, L/min) and end-tidal partial pressure for CO₂ (PETCO₂, mmHg) were obtained breath-by-breath and averaged into 20s bins. Cardiac output (L/min) was assessed continuously by a calibrated signal-morphology impedance cardiography system (Physioflow PF-5TM, Manatec) (Charloux et al., 2000). Arterial oxygen saturation was measured non-invasively by pulse oximetry (SpO₂, %). Breathlessness and leg effort were rated according to the 10-point Borg category-ratio scale every minute. Blood gases were measured from arterialized (art) earlobe capillary samples concomitantly to CBF, i.e., at the 3rd min of each stage as described below.

2.2.3. Cerebral blood flow & oxygenation

Continuous-wave, spatially-resolved near-infrared spectroscopy (NIRS) was used to measure CO_x (changes in oxyhemoglobin concentration ($\Delta[O_2Hb]$, $\mu\text{mol/L}$) and tissue oxygenation index (TOI, %)) and, by injecting the light-absorbing tracer indocyanine green (ICG) dye, (pre-frontal cortical) CBF (Kuebler et al., 1998; Habazettl et al., 2010) (NIRO 200, Hamamatsu Photonics KK, Hamamatsu, Japan). One set of NIRS optodes was placed on the skin over the left pre-frontal cortex region of the forehead, secured using double-sided adhesive tape and hold with a custom-built net headset. The optode separation distance was 4 cm, corresponding to a penetration depth of ~ 2 cm. The spectrophotometer measured ICG concentration following a 5 mg/mL bolus injection of ICG in the right forearm vein. ICG injections were performed during the third minute of exercise. Given that light attenuation is influenced by ICG, O₂Hb and deoxyhaemoglobin, the independent contribution of ICG was assessed using a matrix operation that incorporates pathlength-specific extinction coefficients for each of the light absorbing chromophores (Hamamatsu Photonics KK). As proposed by Kuebler et al. (1998), a CBF index was calculated as the maximal change in ICG divided by its rise time (10–90% amplitude) ($\eta\text{mol/s}$) (Fig. 1).

Table 1
Resting and peak exercise variables in COPD and overlap patients.

| | COPD (n = 10) | Overlap (n = 8) |
|--|---------------|-----------------|
| General characteristics | | |
| Age (yrs) | 65 ± 8 | 65 ± 6 |
| Weight (kg) | 60 ± 8 | 72 ± 5* |
| Height (cm) | 164 ± 78 | 166 ± 28 |
| Body mass index (kg/m ²) | 22 ± 3 | 25 ± 2* |
| Packs/year | 38 ± 7 | 33 ± 5 |
| Left ventricular ejection fraction (%) | 64 ± 13 | 30 ± 5* |
| Main co-morbidities | | |
| Hypertension | 6 | 5 |
| Type II diabetes | 5 | 6 |
| Hypercholesterolemia | 1 | 3 |
| Lung function | | |
| FVC (% pred) | 84 ± 12 | 72 ± 9 |
| FEV ₁ (% pred) | 44 ± 15 | 54 ± 8 |
| FEV ₁ /FVC | 41 ± 11 | 55 ± 7* |
| TLC (% pred) | 111 ± 13 | 87 ± 21* |
| RV (% pred) | 165 ± 30 | 128 ± 35* |
| D _{LCO} (% pred) | 68 ± 21 | 63 ± 4 |
| PaO ₂ (mmHg) | 57 ± 9 | 64 ± 3 |
| PaCO ₂ (mmHg) | 39 ± 6 | 34 ± 1 |
| Peak exercise | | |
| Work rate (W) | 57 ± 18 | 52 ± 16 |
| Work rate (% pred) | 57 ± 16 | 46 ± 15 |
| VO ₂ (mL/min) | 1018 ± 180 | 1080 ± 275 |
| VO ₂ (% pred) | 69 ± 11 | 60 ± 13 |
| VCO ₂ (mL/min) | 1060 ± 259 | 1082 ± 351 |
| RER | 1.06 ± 0.25 | 1.08 ± 0.35 |
| VE (L/min) | 37.7 ± 11.3 | 40.6 ± 14.0 |
| Heart rate (% pred) | 85 ± 13 | 68 ± 18* |
| SpO ₂ (%) | 87 ± 5 | 93 ± 3* |
| Dyspnea score | 7 ± 2 | 9 ± 1 |
| Leg effort score | 7 ± 2 | 10 ± 1* |

Values are mean ± SD or frequencies. Abbreviations: FVC = forced vital capacity; FEV₁ = forced expiratory volume in 1 s; TLC = total lung capacity; RV = residual volume; D_{LCO} = lung diffusing capacity for carbon monoxide; PaO₂ = arterial partial pressure for oxygen; PaCO₂ = arterial partial pressure for carbon dioxide; VO₂ = oxygen uptake; VCO₂ = carbon dioxide production; RER = respiratory exchange ratio; VE = minute ventilation; SpO₂ = oxygen saturation by pulse oximetry.
* p < 0.05.

2.3. Statistical analysis

Results are reported as means ± SD, unless stated otherwise. COPD and overlap patients were contrasted by non-paired *t* or Mann–Whitney's test or a χ^2 test for differences in proportions. Two-way analysis of variance was used to assess between-group differences at a given time point and intra-group differences (exercise vs. rest). Statistical significance was set at *p* < 0.05.

3. Results

3.1. Patients' characteristics at rest and peak exercise

All patients were under triple therapy for COPD (long-acting anti-muscarinics and β_2 -adrenoceptor agonists/inhaled corticosteroids). In addition, overlap patients were receiving selective β -blockers, ACE inhibitors and diuretics. As shown in Table 1, COPD and overlap groups were well-matched by age and main co-morbidities. Overlap patients, however, were heavier than their counterparts with COPD. As expected, while COPD patients showed an obstructive pattern with hyperinflation and air trapping, overlap patients had mixed obstructive and restrictive abnormalities. Lung diffusing capacity (D_{LCO}) did not differ between groups. There were also no between-group differences in WR_{peak} and peak VO₂.

However, peak SpO₂ was lower in overlap compared to COPD (*p* < 0.05). As expected from β -blocker usage, overlap had greater heart rate reserves at exercise termination. Of note, they showed greater symptom burden, particularly regarding to leg effort scores (Table 1).

3.2. Metabolic, ventilatory and sensory responses

As anticipated from similar WR_{peak}, COPD and overlap exercised at similar work rate and metabolic demands (and thus O₂ and VCO₂) at each submaximal exercise intensity (Table 2). Absolute and relative (to VCO₂) ventilatory responses, however, were greater in overlap patients. For instance, while VE increased ~13 L/min from 20% to 80% WR_{peak} in COPD, it increased ~20 L/min in overlap. Consequently, VE/VCO₂ was significantly higher (and PETCO₂ lower) at 60% and 80% WR_{peak} in overlap (*p* < 0.05). Similar to maximal exercise, leg effort scores were higher at 80% WR_{peak} in overlap compared to COPD (Table 2).

3.3. Pulmonary gas exchange responses

There were marked between-group differences in arterial blood gases during exercise. For instance, while SpO₂ (%) progressively decreased in COPD (~10 unities less from rest to 80% WR_{peak}), it remained remarkably stable in overlap (Fig. 2A). As shown in Fig. 2B, Part CO₂ increased by 2–3 mmHg from rest to 20% WR_{peak} in both groups. Thereafter, Part CO₂ remained stable at around 40 mmHg in COPD and decreased by ~3 mmHg from 20% to 80% WR_{peak} in overlap. As a consequence, Part CO₂ at 80% WR_{peak} was significantly lower in overlap compared to COPD (*p* < 0.05).

3.4. Cardiovascular and hemodynamic responses

Stroke volume and, particularly, heart rate were lower from rest to exercise (i.e., rest, 20 and 80% WR_{peak}) in overlap (Fig. 3, upper panels). Thus, cardiac output was downwardly shifted during exercise in that group (i.e., rest, 20 and 80% WR_{peak}; Fig. 3C). In fact, while cardiac output increased more than 5 L/min from rest to 80% WR_{peak} in COPD, it increased only ~2 L/min in overlap (Fig. 3C). Mean arterial pressure was also consistently lower across exercise intensities in overlap (~20 mmHg less; Fig. 3D).

3.5. Cerebral blood flow and oxygenation

Resting CBF in overlap was markedly lower compared to COPD (*p* < 0.01). In addition, whereas CBF increased 41.1 ± 8.9 % from rest to 80% WR_{peak} in COPD it decreased 10.2 ± 8.2 % in overlap. CBF thus remained consistently lower throughout exercise in overlap (Fig. 2C). As shown in Fig. 4, this was related both to lower ICG amplitude and slower rising time (*p* < 0.01). COx analyses showed that the area under the curve of exercising Δ O₂Hb and TOI responses were also significantly lower in overlap compared to COPD (427 ± 110 a.u. vs. 1101 ± 323 a.u. and 5395 ± 230 a.u. vs. 7406 ± 476 a.u., respectively; *p* < 0.01). Furthermore, while discrete Δ HbO₂ values increased on average ~10 μ mol from rest to 80% WR_{peak} in COPD (*p* < 0.05), they failed to increase during exercise in overlap (Fig. 2D).

4. Discussion

This is the first study to demonstrate that marked impairments in resting cerebral (pre-frontal) blood flow (CBF) are further amplified under the stress of exercise in COPD patients presenting heart failure as co-morbidity ("overlap"). Cerebral oxygenation (COx) was

Table 2
Physiological and sensory responses at standardized sub-maximal exercise intensities in COPD and overlap patients.

| | 20% Peak | | 40% Peak | | 60% Peak | | 80% Peak | |
|--|-------------|-------------|-------------|-------------|-------------|-------------|-------------|--------------|
| | COPD | Overlap | COPD | Overlap | COPD | Overlap | COPD | Overlap |
| Work rate (W) | 11 ± 3 | 9 ± 5 | 25 ± 7 | 23 ± 2 | 35 ± 11 | 35 ± 2 | 47 ± 15 | 43 ± 12 |
| VO ₂ (mL/min) | 611 ± 106 | 613 ± 181 | 711 ± 107 | 709 ± 204 | 820 ± 122 | 978 ± 230 | 1032 ± 270 | 982 ± 109 |
| VCO ₂ (mL/min) | 564 ± 110 | 552 ± 200 | 673 ± 132 | 739 ± 250 | 808 ± 181 | 942 ± 330 | 1045 ± 336 | 1082 ± 219 |
| RER | 0.92 ± 0.05 | 0.88 ± 0.06 | 0.94 ± 0.07 | 0.90 ± 0.09 | 0.97 ± 0.08 | 0.83 ± 0.12 | 1.00 ± 0.78 | 1.08 ± 0.09 |
| V _E (L/min) | 21.9 ± 4.8 | 22.7 ± 6.5 | 25.2 ± 5.5 | 29.4 ± 7.5 | 28.4 ± 7.0 | 36.5 ± 8.8* | 34.9 ± 14.5 | 42.1 ± 10.1† |
| V _E /VCO ₂ | 39 ± 5 | 42 ± 5 | 38 ± 4 | 41 ± 4 | 35 ± 5 | 39 ± 2* | 33 ± 6 | 40 ± 5* |
| P _{ET} CO ₂ (mmHg) | 38 ± 5 | 33 ± 5 | 38 ± 5 | 32 ± 4 | 40 ± 6 | 36 ± 3* | 42 ± 7 | 32 ± 6* |
| Dyspnea score | 2 ± 1 | 0.5 ± 1 | 3 ± 2 | 3 ± 1 | 7 ± 4 | 5 ± 3 | 8 ± 3 | 5 ± 2* |
| Leg effort score | 1 ± 0.5 | 2 ± 1 | 2 ± 1 | 4 ± 2 | 4 ± 2 | 6 ± 2 | 5 ± 3 | 9 ± 4* |

COPD vs. overlap. VO₂ = oxygen consumption; VCO₂ = carbon dioxide production; RER = respiratory exchange ratio; V_E; minute ventilation; P_{ET}CO₂ = end tidal partial for carbon dioxide.

* $p < 0.05$.




Fig. 2. Arterial oxygen saturation, arterialized partial pressure of carbon dioxide and cerebral blood flow and oxygenation in COPD (open symbols) and overlap (closed symbols).

* Between-group differences at a given time point; † intra-group differences versus rest.

also significantly reduced in overlap despite better preserved arterial oxygenation compared to COPD without heart failure. These abnormalities were associated with lower systemic perfusion pressure (\downarrow mean arterial pressure) and flow (\downarrow cardiac output) together with lower tensions of a potent cerebral vasodilator (\downarrow PaCO₂). This study sets the scene for future investigations aimed at relating CBF and CO_x with clinically-relevant outcomes in overlap,

including dyspnea, (Higashimoto et al., 2011) exercise intolerance, (Mentz et al., 2013; Oliveira et al., 2014) cerebrovascular disease (Nagayama et al., 2007) and cognitive impairment (Leto and Feola, 2014).

There is growing recognition that heart failure has devastating consequences for patients with COPD (Rutten et al., 2006; Güder and Rutten, 2014). Unfortunately, little is known on how these




Fig. 3. Cardiovascular and hemodynamic responses to discontinuous, incremental exercise test in COPD (open symbols) and overlap (closed symbols). *Between-group differences at a given time point; † intra-group differences versus rest.

complex diseases interact to increase morbidity and mortality. The present study sheds light on a hitherto unexplored pathophysiological consequence of COPD-heart failure coexistence: impaired CBF and COx. The present data show that, while already present at rest, these abnormalities were magnified upon exertion (Fig. 2). This indicates that required adjustments to maintain, or increase, CBF and COx were particularly dysfunctional under challenging physiological conditions in overlap compared to COPD.

In this context, it should be recognized that CBF regulation during exercise is influenced by several physiological factors in addition to cerebral metabolic and neuronal activity (Ogoh and Ainslie, 2009). For instance, previous studies showed that a 1 mmHg increase and decrease in PaCO₂ led to an approximate 3–6% increase and 1–3% decrease in CBF, respectively (as reviewed by Willie et al., 2014). Even considering that potential impairments in cerebrovascular reactivity to CO₂ may have lessened these variations in CBF, (Xie et al., 2005) Part CO₂ (and PETCO₂) in the present study were typically lower during exercise in overlap compared to COPD. It is also noteworthy that between-group differences in Part CO₂ and CBF concomitantly widened from 60% to 80% peak exercise (Fig. 2B and C). Lower Part CO₂ can be explained by greater ventilatory responses to metabolic demand (i.e., higher $\dot{V}E/VCO_2$) found in overlap (Table 2), a well-known physiological correlate of heart failure (Piepoli et al., 2010). Although hyperventilation

likely attenuated exertional hypoxemia (Fig. 2A), this was outweighed by lower CBF as COx was significantly impaired in overlap (Fig. 2D), i.e., O₂ delivery was possibly insufficient to meet cerebral O₂ demands. In contrast, COPD patients maintained stable Part CO₂ values throughout exercise, likely secondary to worsening mechanical-ventilatory constraints (O'Donnell et al., 2014) induced by higher operating lung volumes (Table 1). In this sense, the “protective” effects of exertional hypercapnia on CBF in COPD (Yildiz et al., 2012; Oliveira et al., 2012; Vogiatzis et al., 2013; Hartmann et al., 2014; Cornwell and Levine, 2015; Alosco and Hayes, 2015) may have been offset by alveolar hyperventilation due to higher ventilatory drive in heart failure (Piepoli et al., 2010) combined with COPD.

Another major putative mechanism for impaired CBF in overlap patients was the consistently low mean arterial pressure (Fig. 3D). Although cerebral auto-regulation has long been thought to maintain CBF over a large range of mean arterial pressures, (Lassen, 1959) this has been more recently disputed (Ogoh and Ainslie, 2009). In fact, this seems to be particularly relevant during exercise where relatively mild decrements in mean arterial pressure may impair CBF (Willie et al., 2014). Moreover, there is recent evidence that impairments in cardiac output can negatively influence CBF during exercise, independently of PaCO₂ and cerebral auto-regulation (Ogoh et al., 2005). It could also be argued that negative cardiopulmonary interactions in overlap (in addition to




Fig. 4. Changes in indocyanine green amplitude and rising time as measured by near-infrared spectroscopy in COPD (open symbols) and overlap (closed symbols). *Between-group differences at a given time point; † intra-group differences versus rest.

the negative chronotropic effects of β -blockers) might lead to greater decrements in cardiac output thereby further impairing CBF (Oliveira et al., 2014). In fact, even in COPD patients without heart failure, improvements in cardiac output with non-invasive ventilation (under the same arterial oxygen content) (Rodrigues et al., 2013) had positive effects on COx. Thus, lower cerebral perfusion pressure (\downarrow mean arterial pressure) and/or flow (\downarrow cardiac output) may have compounded with higher intra-cerebral vessel resistance (\downarrow PaCO₂) to impair CBF and COx in overlap. Collectively, these results illustrate the notion that CBF regulation in disease is a complex integrative process that involves pulmonary gas exchange and cardiovascular/hemodynamic function in addition to intracranial mediators of cerebral vessel resistance (Willie et al., 2014).

There are other physiological derangements associated with heart failure that might bear a negative influence on CBF in overlap. Neurohumoral and/or metabolic factors such as the renin-angiotensin system, endothelin, adiponectin and other metabolites

have been related to chronic changes in vascular function (Choi et al., 2006). Although controversial, (van Lieshout and Secher, 2008) it is also conceivable that elevated sympathetic nerve activity may induce cerebral vasoconstriction. In addition, abnormal arterial baroreflex control of sympathetic nerve activity may negatively influence CBF during exercise (Ogoh et al., 2006).

The observed abnormalities on CBF and COx likely have relevant implications for the clinical care of overlap patients. Firstly, low CBF and COx might negatively influence patients' cognition, (Alosco et al., 2014; Leto and Feola, 2014) an important outcome related to disability and quality of life in COPD and heart failure. Secondly, these derangements might lead to reductions in central motor drive to the working muscles ("central fatigue") (Oliveira et al., 2014) and/or increased perception of negative respiratory (Higashimoto et al., 2011) and muscular sensations (Table 1) thereby contributing to early exercise termination. However, COPD and overlap had similar WR_{peak} (Table 1), suggesting

that those impairments did not contribute decisively to reduce peak exercise capacity in the present study. Whether this also holds true for endurance exercise tolerance remains to be investigated. Thirdly, they provide plausible mechanistic bases for the reported greater risk of overlap patients to develop cerebrovascular disease and ischemic stroke (Mentz et al., 2013, 2014). Finally, CBF regulation might also be impaired in other conditions such as COPD exacerbation (Yildiz et al., 2012) heart failure decompensation (Choi et al., 2006) and mechanical ventilation (Cannizzaro et al., 1997). In those challenging situations, our results suggest that extra care should be taken to avoid iatrogenic reductions in cerebral perfusion induced by volume depletion (excessive diuresis), low cardiac output (high intrathoracic pressures) (Oliveira et al., 2014) or sudden decrease in the prevailing PaCO₂ tensions (alveolar hyperventilation) (Cannizzaro et al., 1997).

The present investigation has, naturally, some limitations. CBF index by NIRS is only a relative measure of blood flow, i.e., it is proportional to flow with an unknown factor of proportionality. Thus, BFI is better suited to intra- rather than inter-subject comparisons. (Habazettl et al., 2010) Nevertheless, Fig. 4 shows that both ICG kinetic parameters were consistently different, i.e. lower amplitude and faster rate of increase in overlap compared to controls. Thus, although our results showed a marked decrease in CBF in overlap patients (Fig. 2C), we were unable to precise the extent of those impairments. We used $\Delta\text{O}_2\text{Hb}$ and TOI (which depends on both O₂Hb and deoxy-Hb) to assess changes in COx during incremental exercise. Owing to the fact that fractional O₂ extraction is substantially lower in the cerebral tissue compared to skeletal muscle (Ogoh and Ainslie, 2009) and the influence of venous blood volume on cerebral deoxy-Hb (Hoshi et al., 2001), the former likely reflects better changes in CBF under dynamic conditions. Thus, if HbO₂ and HHb increase proportionally with CBF, cerebral TOI might become relatively stable. In fact, Hoshi et al. (2001) found that HbO₂ was the most sensitive NIRS-based indicator of changes in CBF in a perfused rat brain model. Our patients had no previous history/diagnosis of carotid disease but we cannot rule out the hypothesis that worse extra-cranial atherosclerotic disease contributed to lower CBF in overlap herein (Nagayama et al., 2007). We acknowledge that our sample is relatively small and certainly not representative of the whole spectrum of COPD and heart failure severity. Nevertheless, it is unlikely that systematic type II error was present as most of the between-group differences were sufficiently large to reach statistical significance at the 5% level. The impact of heart failure on patients with end-stage COPD showing overt respiratory insufficiency at rest (i.e., hypoxemia and/or hypercapnia) (Jensen et al., 2002) remains to be investigated.

In conclusion, this is the first demonstration that marked impairments in resting CBF are worsened by the stress of exercise in COPD patients presenting heart failure as co-morbidity. These abnormalities precluded COx to increase throughout exercise, a likely consequence of the combined deleterious effects of systemic hemodynamic impairment and lower PaCO₂ in overlap. If CBF and COx prove to be associated with clinically-relevant outcomes (e.g., dyspnea, exercise intolerance, cerebrovascular disease and cognitive impairment), cerebral hemodynamics and oxygenation may become useful therapeutic targets for overlap patients.

Conflict of interest

All authors declare that they have no conflict of interest related to the present study.

References

- Alosco, M.L., Hayes, S.M., 2015. Structural brain alterations in heart failure: a review of the literature and implications for risk of Alzheimer's disease. *Heart Fail. Rev.* 20, 561–571.
- Alosco, M.L., Spitznagel, M.B., Josephson, R., Hughes, J., Gunstad, J., 2014. COPD is associated with cognitive dysfunction and poor physical fitness in heart failure. *Heart Lung* 44, 21–26.
- Brassard, P., Ainslie, P.N., Secher, N.H., 2014. Cerebral oxygenation in health and disease. *Front Physiol.* 5, 458.
- Cannizzaro, G., Garbin, L., Clivati, A., Pesce, L.L., 1997. Correction of hypoxia and hypercapnia in COPD patients: effects on cerebrovascular flow. *Monaldi Arch. Chest Dis.* 52, 9–12.
- Charloux, A., Lonsdorfer-Wolf, E., Richard, R., Lampert, E., Oswald-Mammosser, M., Mettauer, B., Geny, B., Lonsdorfer, J., 2000. A new impedance cardiograph device for the non-invasive evaluation of cardiac output at rest and during exercise: comparison with the "direct" Fick method. *Eur. J. Appl. Physiol.* 82, 313–320.
- Choi, B.-R., Kim, J.S., Yang, Y.J., Park, K.-M., Lee, C.W., Kim, Y.-H., Hong, M.-K., Song, J.-K., Park, S.-W., Park, S.-J., Kim, J.-J., 2006. Factors associated with decreased cerebral blood flow in congestive heart failure secondary to idiopathic dilated cardiomyopathy. *Am. J. Cardiol.* 97, 1365–1369.
- Cornwell, W.K., Levine, B.D., 2015. Patients with heart failure with reduced ejection fraction have exaggerated reductions in cerebral blood flow during upright posture. *JACC Heart Fail.* 3, 176–179.
- Fu, T.-C., Wang, C.-H., Hsu, C.-C., Cherng, W.-J., Huang, S.-C., Wang, J.-S., 2011. Suppression of cerebral hemodynamics is associated with reduced functional capacity in patients with heart failure. *Am. J. Physiol. Heart Circ. Physiol.* 300, H1545–1555.
- Güder, G., Rutten, F.H., 2014. Comorbidity of heart failure and chronic obstructive pulmonary disease: more than coincidence. *Curr. Heart Fail. Rep.* 11, 337–346.
- Habazettl, H., Athanasopoulos, D., Kuebler, W.M., Wagner, H., Roussos, C., Wagner, P.D., Ungruhe, J., Zakynthinos, S., Vogiatzis, I., 2010. Near-infrared spectroscopy and indocyanine green derived blood flow index for noninvasive measurement of muscle perfusion during exercise. *J. Appl. Physiol.* 108, 962–967.
- Hartmann, S.E., Leigh, R., Poulin, M.J., 2014. Cerebrovascular responses to submaximal exercise in women with COPD. *BMC Pulm. Med.* 14, 99.
- Higashimoto, Y., Honda, N., Yamagata, T., Matsuoka, T., Maeda, K., Satoh, R., Nishiyama, O., Sano, H., Iwanaga, T., Miyara, T., Muraki, M., Tomita, K., Kume, H., Miyai, I., Tohda, Y., Fukuda, K., 2011. Activation of the prefrontal cortex is associated with exertional dyspnea in chronic obstructive pulmonary disease. *Respiration* 82, 492–500.
- Hoshi, Y., Kobayashi, N., Tamura, M., 2001. Interpretation of near-infrared spectroscopy signals: a study with a newly developed perfused rat brain model. *J. Appl. Physiol.* 90, 1657–1662.
- Jensen, G., Nielsen, H.B., Ide, K., Madsen, P.L., Svendsen, L.B., Svendsen, U.G., Secher, N.H., 2002. Cerebral oxygenation during exercise in patients with terminal lung disease. *Chest* 122, 445–450.
- Kim, M.-S., Kim, J.-S., Yun, S.-C., Lee, C.-W., Song, J.-K., Park, S.-W., Park, S.-J., Kim, J.-J., 2012. Association of cerebral blood flow with the development of cardiac death or urgent heart transplantation in patients with systolic heart failure. *Eur. Heart J.* 33, 354–362.
- Kim, Y.-S., Seifert, T., Brassard, P., Rasmussen, P., Vaag, A., Nielsen, H.B., Secher, N.H., van Lieshout, J.J., 2015. Impaired cerebral blood flow and oxygenation during exercise in type 2 diabetic patients. *Physiol. Rep.* 3, e12430.
- Koike, A., Hoshimoto, M., Tajima, A., Nagayama, O., Yamaguchi, K., Goda, A., Yamashita, T., Sagara, K., Itoh, H., Aizawa, T., 2006. Critical level of cerebral oxygenation during exercise in patients with left ventricular dysfunction. *Circ.* 114, 1457–1461.
- Koike, A., Itoh, H., Oohara, R., Hoshimoto, M., Tajima, A., Aizawa, T., Fu, L.T., 2004. Cerebral oxygenation during exercise in cardiac patients. *Chest* 125, 182–190.
- Kuebler, W.M., Sckell, A., Habler, O., Kleen, M., Kuhnle, G.E., Welte, M., Messmer, K., Goetz, A.E., 1998. Noninvasive measurement of regional cerebral blood flow by near-infrared spectroscopy and indocyanine green. *J. Cereb. Blood Flow Metab.* 18, 445–456.
- Lassen, N.A., 1959. Cerebral blood flow and oxygen consumption in man. *Physiol. Rev.* 39, 183–238.
- Leto, L., Feola, M., 2014. Cognitive impairment in heart failure patients. *J. Geriatr. Cardiol.* 11, 316–328.
- Mentz, R.J., Kelly, J.P., von Lueder, T.G., Voors, A.A., Lam, C.S.P., Cowie, M.R., Kjeldsen, K., Jankowska, E.A., Atar, D., Butler, J., Fiuza, M., Zannad, F., Pitt, B., O'Connor, C.M., 2014. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. *J. Am. Coll. Cardiol.* 64, 2281–2293.
- Mentz, R.J., Schulte, P.J., Fleg, J.L., Fiuza, M., Kraus, W.E., Piña, I.L., Keteyian, S.J., Kitzman, D.W., Whellan, D.J., Ellis, S.J., O'Connor, C.M., 2013. Clinical characteristics response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION). *Am. Heart J.* 165, 193–199.
- Nagayama, O., Koike, A., Hoshimoto, M., Yamaguchi, K., Tajima, A., Goda, A., Uejima, T., Itoh, H., Aizawa, T., 2007. Influence of cerebrovascular arteriosclerosis on cerebral oxygenation during exercise. *Circ.* 115, 782–787.
- O'Donnell, D.E., Laveneziana, P., Webb, K., Nader, J.A., 2014. Chronic obstructive pulmonary disease: clinical integrative physiology. *Clin. Chest Med.* 35, 51–69.
- Ogoh, S., Ainslie, P.N., 2009. Cerebral blood flow during exercise: mechanisms of regulation. *J. Appl. Physiol.* 107, 1370–1380.

- Ogoh, S., Brothers, R.M., Barnes, Q., Eubank, W.L., Hawkins, M.N., Purkayastha, S., O-Yurvati, A., Raven, P.B., 2006. Effects of changes in central blood volume on carotid-vasomotor baroreflex sensitivity at rest and during exercise. *J. Appl. Physiol.* 101, 68–75.
- Ogoh, S., Brothers, R.M., Barnes, Q., Eubank, W.L., Hawkins, M.N., Purkayastha, S., O-Yurvati, A., Raven, P.B., 2005. The effect of changes in cardiac output on middle cerebral artery mean blood velocity at rest and during exercise. *J. Physiol.* 569, 697–704.
- Oliveira, M.F., Arbex, F., Alencar, M.C.N., Soares, A., Borghi-Silva, A., Almeida, D., Neder, J.A., 2013. Heart failure impairs cerebral oxygenation during exercise in patients with COPD. *Eur. Respir. J.* 42, 1423–1426.
- Oliveira, M.F., Rodrigues, M.K., Treptow, E., Cunha, T.M., Ferreira, E.M.V., Neder, J.A., 2012. Effects of oxygen supplementation on cerebral oxygenation during exercise in chronic obstructive pulmonary disease patients not entitled to long-term oxygen therapy. *Clin. Physiol. Funct. Imaging* 32, 52–58.
- Oliveira, M.F., Zelt, J.T.J., Jones, J.H., Hirai, D.M., O'Donnell, D.E., Verges, S., Neder, J.A., 2014. Does impaired O₂ delivery during exercise accentuate central and peripheral fatigue in patients with coexistent COPD–CHF? *Front. Physiol.* 5, 514.
- Piepoli, M.F., Guazzi, M., Boriani, G., Cicoira, M., Corrà, U., Dalla Libera, L., Emdin, M., Mele, D., Passino, C., Vescovo, G., Vigorito, C., Villani, G.Q., Agostoni, P., 2010. Exercise intolerance in chronic heart failure: mechanisms and therapies. Part I. *Eur. J. Cardiovasc. Prev. Rehabil.* 17, 637–642.
- Rodrigues, M.K., Oliveira, M.F., Soares, A., Treptow, E., Neder, J.A., 2013. Additive effects of non-invasive ventilation to hyperoxia on cerebral oxygenation in COPD patients with exercise-related O₂ desaturation. *Clin. Physiol. Funct. Imaging* 33, 274–281.
- Rutten, F.H., Cramer, M.-J.M., Lammers, J.-W.J., Grobbee, D.E., Hoes, A.W., 2006. Heart failure and chronic obstructive pulmonary disease: an ignored combination? *Eur. J. Heart Fail.* 8, 706–711.
- Van de Ven, M.J., Colier, W.N., Van der Sluijs, M.C., Kersten, B.T., Oeseburg, B., Folgering, H., 2001. Ventilatory and cerebrovascular responses in normocapnic and hypercapnic COPD patients. *Eur. Respir. J.* 18, 61–68.
- van Lieshout, J.J., Secher, N.H., 2008. Point: counterpoint: sympathetic activity does/does not influence cerebral blood flow: point: sympathetic activity does influence cerebral blood flow. *J. Appl. Physiol.* 105, 1364–1366.
- Vestbo, J., Hurd, S.S., Agustí, A.G., Jones, P.W., Vogelmeier, C., Anzueto, A., Barnes, P.J., Fabbri, L.M., Martinez, F.J., Nishimura, M., Stockley, R.A., Sin, D.D., Rodriguez-Roisin, R., 2013. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am. J. Respir. Crit. Care Med.* 187, 347–365.
- Vogiatzis, I., Louvaris, Z., Habazettl, H., Andrianopoulos, V., Wagner, H., Roussos, C., Wagner, P.D., Zakyntinos, S., 2013. Cerebral cortex oxygen delivery and exercise limitation in patients with COPD. *Eur. Respir. J.* 41, 295–301.
- Willie, C.K., Tzeng, Y.-C., Fisher, J.A., Ainslie, P.N., 2014. Integrative regulation of human brain blood flow. *J. Physiol.* 592, 841–859.
- Xie, A., Skatrud, J.B., Khayat, R., Dempsey, J.A., Morgan, B., Russell, D., 2005. Cerebrovascular response to carbon dioxide in patients with congestive heart failure. *Am. J. Respir. Crit. Care Med.* 172, 371–378.
- Yildiz, S., Kaya, I., Cece, H., Gencer, M., Ziyilan, Z., Yalcin, F., Turksoy, O., 2012. Impact of COPD exacerbation on cerebral blood flow. *Clin. Imaging* 36, 185–190.